Clinical Trials Logo

Filter by:
NCT ID: NCT00002129 Completed - HIV Infections Clinical Trials

A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3

Start date: n/a
Phase: Phase 1
Study type: Interventional

To examine the safety and tolerance of three doses of oral vesnarinone in HIV-infected patients with CD4 count > 300 cells/mm3.

NCT ID: NCT00002130 Completed - HIV Infections Clinical Trials

A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

Start date: n/a
Phase: N/A
Study type: Interventional

To examine the continued safety and tolerability of four doses of vesnarinone in HIV-infected patients who have completed a short-term study (less than 12 months on continuous treatment) of the drug.

NCT ID: NCT00002131 Completed - HIV Infections Clinical Trials

A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

To examine the safety and efficacy of two doses of vesnarinone in patients with AIDS-related Kaposi's sarcoma.

NCT ID: NCT00002132 Completed - HIV Infections Clinical Trials

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

Start date: n/a
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of itraconazole oral solution versus fluconazole tablets for the treatment of esophageal candidiasis in immunocompromised patients.

NCT ID: NCT00002133 Completed - HIV Infections Clinical Trials

An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.

Start date: n/a
Phase: N/A
Study type: Interventional

To assess the efficacy and safety of itraconazole oral solution in HIV-seropositive patients with oropharyngeal candidiasis that is refractory to fluconazole.

NCT ID: NCT00002134 Completed - HIV Infections Clinical Trials

A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis

Start date: n/a
Phase: N/A
Study type: Interventional

To demonstrate the efficacy of oral ganciclovir in preventing new cytomegalovirus (CMV) disease in AIDS patients with unilateral CMV retinitis treated with an intravitreal ganciclovir implant. To compare safety and tolerance, time to progression, quality of life, and survival among patients treated with an intravitreal ganciclovir implant, with and without oral ganciclovir, versus standard intravenous (IV) ganciclovir therapy.

NCT ID: NCT00002135 Completed - HIV Infections Clinical Trials

An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

Start date: n/a
Phase: N/A
Study type: Interventional

To provide oral ganciclovir to patients who require maintenance for control of cytomegalovirus (CMV) retinitis, but who lack patent permanent central venous access for long-term administration of intravenous drugs.

NCT ID: NCT00002136 Completed - HIV Infections Clinical Trials

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

Start date: n/a
Phase: Phase 1
Study type: Interventional

To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.

NCT ID: NCT00002137 Completed - HIV Infections Clinical Trials

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

Start date: n/a
Phase: Phase 1
Study type: Interventional

To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.

NCT ID: NCT00002138 Completed - HIV Infections Clinical Trials

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

Start date: n/a
Phase: Phase 1
Study type: Interventional

To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.